Acid-Activatable Theranostic Unimolecular Micelles Composed of Amphiphilic Star-like Polymeric Prodrug with High Drug Loading for Enhanced Cancer Therapy. 2017

Xiaoxiao Shi, and Meili Hou, and Shuang Bai, and Xiaoqian Ma, and Yong-E Gao, and Bo Xiao, and Peng Xue, and Yuejun Kang, and Zhigang Xu, and Chang Ming Li
Institute for Clean Energy and Advanced Materials, Faculty of Materials and Energy, Southwest University , Chongqing 400715, P. R. China.

Stimuli-responsive nanomedicine with theranostic functionalities with reduced side-effects has attracted growing attention, although there are some major obstacles to overcome before clinical applications. Herein, we present an acid-activatable theranostic unimolecular micelles based on amphiphilic star-like polymeric prodrug to systematically address typical existing issues. This smart polymeric prodrug has a preferable size of about 35 nm and strong micellar stability in aqueous solution, which is beneficial to long-term blood circulation and efficient extravasation from tumoral vessels. Remarkably, the polymeric prodrug has a high drug loading rate up to 53.1 wt%, which induces considerably higher cytotoxicity against tumor cells (HeLa cells and MCF-7 cells) than normal cells (HUVEC cells) suggesting a spontaneous tumor-specific targeting capability. Moreover, the polymeric prodrug can serve as a fluorescent nanoprobe activated by the acidic microenvironment in tumor cells, which can be used as a promising platform for tumor diagnosis. The superior antitumor effect in this in vitro study demonstrates the potential of this prodrug as a promising platform for drug delivery and cancer therapy.

UI MeSH Term Description Entries
D008823 Micelles Particles consisting of aggregates of molecules held loosely together by secondary bonds. The surface of micelles are usually comprised of amphiphatic compounds that are oriented in a way that minimizes the energy of interaction between the micelle and its environment. Liquids that contain large numbers of suspended micelles are referred to as EMULSIONS. Micelle
D011108 Polymers Compounds formed by the joining of smaller, usually repeating, units linked by covalent bonds. These compounds often form large macromolecules (e.g., BIOPOLYMERS; PLASTICS). Polymer
D011355 Prodrugs A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. Drug Precursor,Drug Precursors,Pro-Drug,Prodrug,Pro-Drugs,Precursor, Drug,Precursors, Drug,Pro Drug,Pro Drugs
D004337 Drug Carriers Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers. Drug Carrier
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D016503 Drug Delivery Systems Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity. Drug Targeting,Delivery System, Drug,Delivery Systems, Drug,Drug Delivery System,Drug Targetings,System, Drug Delivery,Systems, Drug Delivery,Targeting, Drug,Targetings, Drug
D061307 Human Umbilical Vein Endothelial Cells Endothelial cells that line venous vessels of the UMBILICAL CORD. Human Umbilical Vein Endothelial Cell,Endothelial Cells, Human Umbilical Vein,HUVEC Cells,Cell, HUVEC,Cells, HUVEC,HUVEC Cell
D061986 MCF-7 Cells An estrogen responsive cell line derived from a patient with metastatic human breast ADENOCARCINOMA (at the Michigan Cancer Foundation.) MCF7 Cells,Michigan Cancer Foundation 7 Cells,Cell, MCF-7,Cell, MCF7,Cells, MCF-7,Cells, MCF7,MCF 7 Cells,MCF-7 Cell,MCF7 Cell

Related Publications

Xiaoxiao Shi, and Meili Hou, and Shuang Bai, and Xiaoqian Ma, and Yong-E Gao, and Bo Xiao, and Peng Xue, and Yuejun Kang, and Zhigang Xu, and Chang Ming Li
November 2015, Chemical communications (Cambridge, England),
Xiaoxiao Shi, and Meili Hou, and Shuang Bai, and Xiaoqian Ma, and Yong-E Gao, and Bo Xiao, and Peng Xue, and Yuejun Kang, and Zhigang Xu, and Chang Ming Li
July 2011, Biomacromolecules,
Xiaoxiao Shi, and Meili Hou, and Shuang Bai, and Xiaoqian Ma, and Yong-E Gao, and Bo Xiao, and Peng Xue, and Yuejun Kang, and Zhigang Xu, and Chang Ming Li
June 2015, Journal of materials chemistry. B,
Xiaoxiao Shi, and Meili Hou, and Shuang Bai, and Xiaoqian Ma, and Yong-E Gao, and Bo Xiao, and Peng Xue, and Yuejun Kang, and Zhigang Xu, and Chang Ming Li
April 2019, International journal of molecular sciences,
Xiaoxiao Shi, and Meili Hou, and Shuang Bai, and Xiaoqian Ma, and Yong-E Gao, and Bo Xiao, and Peng Xue, and Yuejun Kang, and Zhigang Xu, and Chang Ming Li
March 2017, Macromolecular bioscience,
Xiaoxiao Shi, and Meili Hou, and Shuang Bai, and Xiaoqian Ma, and Yong-E Gao, and Bo Xiao, and Peng Xue, and Yuejun Kang, and Zhigang Xu, and Chang Ming Li
September 2011, Biomaterials,
Xiaoxiao Shi, and Meili Hou, and Shuang Bai, and Xiaoqian Ma, and Yong-E Gao, and Bo Xiao, and Peng Xue, and Yuejun Kang, and Zhigang Xu, and Chang Ming Li
August 2000, Journal of controlled release : official journal of the Controlled Release Society,
Xiaoxiao Shi, and Meili Hou, and Shuang Bai, and Xiaoqian Ma, and Yong-E Gao, and Bo Xiao, and Peng Xue, and Yuejun Kang, and Zhigang Xu, and Chang Ming Li
August 2017, Molecular pharmaceutics,
Xiaoxiao Shi, and Meili Hou, and Shuang Bai, and Xiaoqian Ma, and Yong-E Gao, and Bo Xiao, and Peng Xue, and Yuejun Kang, and Zhigang Xu, and Chang Ming Li
February 2013, Pharmaceutical research,
Xiaoxiao Shi, and Meili Hou, and Shuang Bai, and Xiaoqian Ma, and Yong-E Gao, and Bo Xiao, and Peng Xue, and Yuejun Kang, and Zhigang Xu, and Chang Ming Li
January 2021, Frontiers in chemistry,
Copied contents to your clipboard!